Biogen News and Research

RSS
Santarus expands development pipeline, adds two novel biologic drug candidates

Santarus expands development pipeline, adds two novel biologic drug candidates

iPierian raises $28 million from Series B equity financing closure

iPierian raises $28 million from Series B equity financing closure

Biogen to publish data on two-step assay for anti-JC virus antibody detection

Biogen to publish data on two-step assay for anti-JC virus antibody detection

Knopp Neurosciences enters $345 million worldwide licensing agreement with Biogen Idec

Knopp Neurosciences enters $345 million worldwide licensing agreement with Biogen Idec

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Systemic lupus erythematosus drug market to quadruple from $400 million in 2009 to over $1.6 billion in 2019

Systemic lupus erythematosus drug market to quadruple from $400 million in 2009 to over $1.6 billion in 2019

Alnylam second-quarter revenues increase to $26.6 million

Alnylam second-quarter revenues increase to $26.6 million

Anadys second-quarter net loss decreases to $3.0 million

Anadys second-quarter net loss decreases to $3.0 million

AVEO second-quarter total revenues increase to $15.6 million

AVEO second-quarter total revenues increase to $15.6 million

Compound Management & Integrity conference to address challenges in improvement methodologies

Compound Management & Integrity conference to address challenges in improvement methodologies

Elan total revenue increases 10% to $579.4 million for first half of 2010

Elan total revenue increases 10% to $579.4 million for first half of 2010

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Neurologists more aware of Merck Serono/EMD Serono's oral cladribine than Novartis/Mitsubishi Tanabe's FTY-720

Neurologists more aware of Merck Serono/EMD Serono's oral cladribine than Novartis/Mitsubishi Tanabe's FTY-720

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B

Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B

Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study

Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin